STOCK MARKET BSE NSE

Biocon Net Dips 54% at Rs 113 cr

Published: 26th April 2014 06:00 AM  |   Last Updated: 26th April 2014 01:08 AM   |  A+A-

Biotechnology major Biocon reported a 54.51% decline in net profit at Rs 113.08 crore in the fourth quarter (Q4) of FY14. The company had posted a `248.61 crore net profit in the same period FY13.

While net sales were up to Rs 722.59 crore in Q4 when compared to Rs 630.12 crore in Q4 Fy13, the company saw its  net profit for FY14 down 18.69% to Rs 413.72 crore from Rs 508.82 crore.

“We continue our efforts to rebalance our product portfolio in the biopharma segment to ensure higher margin accretion despite the underlying current of commoditisation in some of our key product portfolios,” Kiran Mazumdar Shaw, Chairperson and Managing Director of the Bangalore-based company said in a statement.

Meanwhile, Arun Chandavarkar has been appointed as the CEO and Joint MD of Biocon. The company’s board also recommended a final dividend of Rs 5 per share (100 per cent) for the FY 2013-14.

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp